Keyphrases
Inflammatory Bowel Disease
100%
Crohn's Disease
80%
Tumour Necrosis Factor Inhibitor (TNFi)
29%
Magnetic Resonance Enterography
23%
Ulcerative Colitis
22%
Perianal Crohn's Disease
21%
Adverse Event Reporting System
19%
Vedolizumab
18%
Computed Tomography
17%
Ustekinumab
17%
Adverse Events
16%
Small Bowel Crohn's Disease
14%
Chronic Inflammatory Diseases
14%
Confidence Interval
14%
Non-alcoholic Fatty Liver Disease (NAFLD)
14%
Stricture
14%
COVID-19
13%
Thiopurines
12%
Disease Activity
12%
Anti-tumor Necrosis Factor (anti-TNF)
11%
Monotherapy
11%
Ischemic Colitis
11%
Immunomodulator
10%
Computed Tomography Enterography
10%
Odds Ratio
10%
Pouch
10%
Fistula
9%
Tofacitinib
9%
Perianal Fistula
9%
Crohn's Disease of the Pouch
9%
Infliximab
9%
Medical Management
9%
Clinical Trials
9%
Risk Factors
8%
Remission
8%
Bariatric Surgery
8%
Medical Therapy
8%
Disease Severity
7%
Vaccination
7%
Ileal Pouch-anal Anastomosis
7%
Response to Therapy
7%
United States
7%
Small Intestine
7%
Clinical Practice
7%
Inflammation
7%
Crohn's Colitis
7%
Small Molecules
7%
Combination Therapy
6%
Radiologists
6%
Inflammatory Conditions
6%
Medicine and Dentistry
Crohn's Disease
82%
Inflammatory Bowel Disease
62%
Patient with Inflammatory Bowel Disease
28%
Disease
27%
Magnetic Resonance Enterography
23%
Ulcerative Colitis
21%
Patient with Crohn's Disease
18%
Computer Assisted Tomography
16%
Disease Activity
15%
Pouchitis
13%
Fistula
12%
Diagnosis
11%
Combination Therapy
11%
Nonalcoholic Fatty Liver
11%
Ileo-Anal Pouch
10%
Computed Tomography Enterography
10%
Biological Product
9%
Symptom
9%
Tumor Necrosis Factor
9%
Anal Fistula
8%
Fluorodeoxyglucose F 18
8%
Bariatric Surgery
8%
Vedolizumab
8%
Stricture
8%
Disease Course
7%
TNF Inhibitor
7%
Ustekinumab
7%
Serositis
7%
Adverse Event
7%
Drug Therapy
7%
Magnetic Resonance Imaging
7%
Positron Emission Tomography-Computed Tomography
7%
Biological Therapy
6%
Endoscopy
6%
Biological Marker
6%
Dysplasia
6%
Ischemic Colitis
5%
Cancer
5%
Coeliac Disease
5%
Patient-Reported Outcome
5%
Clinical Trial
5%
Immunomodulating Agent
5%
Odds Ratio
5%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
56%
Crohn's Disease
50%
Adverse Event
41%
Tumor Necrosis Factor Inhibitor
33%
Ulcerative Colitis
17%
Tumor Necrosis Factor
14%
Ustekinumab
13%
Mercaptopurine
13%
Biological Product
13%
Disease
12%
Combination Therapy
12%
Remission
11%
Immunomodulating Agent
11%
Inflammatory Disease
11%
Vedolizumab
11%
Monotherapy
10%
Vaccination Policy
10%
Tofacitinib
9%
Infection
8%
Infliximab
8%
Aminosalicylic Acid
8%
Rheumatoid Arthritis
7%
SARS Coronavirus
6%
Clinical Trial
6%
Immunogenicity
5%
Ischemic Colitis
5%
Sodium Dihydrogen Phosphate
5%
Pharmacokinetics
5%